Litcius/Paper detail

Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study

Erika Hamilton, Virginia Kaklamani, Carla I. Falkson, Gregory A. Vidal, Patrick J. Ward, Monika Patre, Jane Yuet Ching Hui, Jacob Rotmensch, Kushagra Gupta, Luciana Molinero, Yijin Li, Leisha A. Emens

2021Clinical Breast Cancer34 citationsDOI

Topics & Concepts

AtezolizumabPertuzumabMedicineTrastuzumabDocetaxelOncologyMetastatic breast cancerInternal medicineBreast cancerCancerImmunotherapyNivolumabHER2/EGFR in Cancer ResearchCancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study | Litcius